Development of PSMA-specific immunotherapy for prostate cancer with PIN4 gene-modified T cells

被引：0
|
作者：
Papa, Sophie [1 ]
Emami-Shahri, Nia [1 ]
Liu, Zhe [1 ]
Petrausch, Ulf [2 ]
Mullen, Gregory [3 ]
Spicer, James [1 ]
Maher, John [1 ]
机构：
[1] Kings Coll London, Dept Res Oncol, Div Canc Studies, London, England
[2] Univ Zurich Hosp, CH-8091 Zurich, Switzerland
[3] Kings Coll London, Dept Imaging Biol, Div Canc Studies, London, England
来源：
LANCET | 2014年 / 383卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：77 / 77
页数：1
相关论文
共 50 条
  • [21] PSMA-specific theranostic nanoplex for combination of TRAIL gene and 5-FC prodrug therapy of prostate cancer
    Chen, Zhihang
    Penet, Marie-France
    Krishnamachary, Balaji
    Banerjee, Sangeeta R.
    Pomper, Martin G.
    Bhujwalla, Zaver M.
    BIOMATERIALS, 2016, 80 : 57 - 67
  • [22] Immunotherapy with gene-modified T cells: limiting side effects provides new challenges
    Stauss, H. J.
    Morris, E. C.
    GENE THERAPY, 2013, 20 (11) : 1029 - 1032
  • [23] Potential for the use of gene-modified Vγ9Vδ2T cells for cancer immunotherapy
    Wang, Yizheng
    Okumura, Saitoshi
    Wang, Linan
    Seo, Naohiro
    Amaishi, Yasunori
    Okamoto, Sachiko
    Mineno, Junichi
    Tanaka, Yoshimasa
    Kato, Takuma
    Shiku, Hiroshi
    CANCER SCIENCE, 2022, 113 : 1783 - 1783
  • [24] A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells
    P. Wolf
    D. Gierschner
    P. Bühler
    U. Wetterauer
    U. Elsässer-Beile
    Cancer Immunology, Immunotherapy, 2006, 55 : 1367 - 1373
  • [25] Immunotherapy with gene-modified T cells: limiting side effects provides new challenges
    H J Stauss
    E C Morris
    Gene Therapy, 2013, 20 : 1029 - 1032
  • [26] Adoptive Immunotherapy for Hematological Malignancies Using T Cells Gene-Modified to Express Tumor Antigen-Specific Receptors
    Fujiwara, Hiroshi
    PHARMACEUTICALS, 2014, 7 (12): : 1049 - 1068
  • [27] PSMA-specific, TGF-β-insensitive CD8+ T cells derived from metastatic castration resistant prostate cancer (mCRPC) patients induce apoptosis of PSMA positive prostate cancer (PCa)
    Zhang, Qiang
    Helfand, Brian
    Yang, Ximing
    Carneiro, Benedito
    Giles, Francis J.
    Kuzel, Timothy
    Lee, Chung
    Cristofanilli, Massimo
    CANCER RESEARCH, 2018, 78 (13)
  • [28] ADOPTIVE TRANSFER OF PSMA-SPECIFIC, TGF-β INSENSITIVE MEMORY CD8+T CELLS: SUPPRESSION OF HUMAN PROSTATE CANCER (CAP)
    Zhang, Qiang
    Helfand, Brian
    Chen, Lin
    Qin, Weijun
    Smith, Norm
    Zhu, Julie
    Guo, Yinglu
    Lee, Chung
    JOURNAL OF UROLOGY, 2010, 183 (04): : E265 - E266
  • [29] A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells
    Wolf, P.
    Gierschner, D.
    Buehler, P.
    Wetterauer, U.
    Elsaesser-Beile, U.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (11) : 1367 - 1373
  • [30] PSMA-specific CARTyrin T-stem cell memory therapy eliminates solid tumor in subcutaneous prostate cancer model
    Smith, Jenessa B.
    Codde, Rebecca
    Tan, Yening
    Barnett, Burton E.
    Hermanson, David
    Rengarajan, Srinivas
    Ostertag, Eric M.
    Shedlock, Devon J.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
12345